Participants
trauma fractures, cancer
UNCONTROLLED HYPERTENSION, CLOTTING DISORDERS, METABOLIC BONE DISEASE, CANCER, MALABSORPTION SYNDROME, SEVERE OBESITY, SEIZURE DISORDERS, HEART ATTACK, THROMBOEMBOLISMS
Thirty-five postmenopausal women aged 45–70 y who were >4 y post natural menopause or had a total hysterectomy were recruited from the Lafayette, IN area with the use of fliers and online advertisements between February and June 2017. Each woman signed a written consent form and completed a screening that included height and weight measurements, a brief medical history, diet, and physical activity assessment. All participants were healthy, as verified by serum biochemistries, including a comprehensive metabolic panel. Exclusion criteria included having a history of metabolic bone disease, personal history or family history of low trauma fractures, personal history of cancer, thromboembolisms, clotting disorders, uncontrolled hypertension, uncontrolled thyroid function, malabsorption syndrome, seizure disorders, heart attack, or severe obesity (BMI > 35 kg/mCONSORT chart. The chart shows participant progress through the study phases.Eighteen women received an intravenous injection of 50 nCi of 